Developing and applying a gene functional association network for anti-angiogenic kinase inhibitor activity assessment in an angiogenesis co-culture model

BMC Genomics

Volumn 9, Issue , 2008, Pages

  Chen, Yuefeng ^a   Wei, Tao ^a   Yan, Lei ^a   Lawrence, Frank ^a   Qian, Hui Rong ^a   Burkholder, Timothy P ^a   Starling, James J ^a   Yingling, Jonathan M ^a   Shou, Jianyong ^a,b  

^a ELI LILLY AND COMPANY   (United States)

^b Novartis Institutes for Biomedical Research   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; LY 2401401; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SUNITINIB; VATALANIB; PROTEIN KINASE INHIBITOR;

ADULT; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOPROCESS; CELL TRANSPORT; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; GENE FUNCTION; GENETIC ALGORITHM; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; NEWBORN; ONCOGENE; SKIN FIBROBLAST; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; UMBILICAL CORD; ALGORITHM; BIOASSAY; BIOLOGICAL MODEL; CELL COMMUNICATION; CYTOLOGY; DERMIS; DNA MICROARRAY; DRUG EFFECT; FIBROBLAST; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; NEOVASCULARIZATION (PATHOLOGY); PHENOTYPE; UMBILICAL VEIN;

ALGORITHMS; ANGIOGENESIS INHIBITORS; BIOLOGICAL ASSAY; CELL COMMUNICATION; COCULTURE TECHNIQUES; DERMIS; ENDOTHELIAL CELLS; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; PHENOTYPE; PROTEIN KINASE INHIBITORS; UMBILICAL VEINS;

EID: 46049088308     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-9-264     Document Type: Article

References (43)

1. Folkman J Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 2007, 6(4):273-286 10.1038/nrd2115 17396134
2. Carmeliet P Angiogenesis in life, disease and medicine Nature 2005, 438(7070):932-936 10.1038/nature04478 16355210
3. Hanahan D Weinberg RA The hallmarks of cancer Cell 2000, 100(1):57-70 10.1016/S0092-8674(00)81683-9 10647931
4. Hanahan D Folkman J Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 1996, 86(3):353-364 10.1016/ S0092-8674(00)80108-7 8756718
5. Naumov GN Akslen LA Folkman J Role of angiogenesis in human tumor dormancy: Animal models of the angiogenic switch Cell Cycle 2006, 5(16):1779-1787 16931911
6. Folkman J Tumor angiogenesis: Therapeutic implications N Engl J Med 1971, 285(21):1182-1186 4938153
7. Ferrara N Kerbel RS Angiogenesis as a therapeutic target Nature 2005, 438(7070):967-974 10.1038/nature04483 16355214
8. Folkman J Klagsbrun M Angiogenic factors Science 1987, 235(4787):442-447 10.1126/science.2432664 2432664
9. Carmeliet P Tessier-Lavigne M Common mechanisms of nerve and blood vessel wiring Nature 2005, 436(7048):193-200 10.1038/nature03875 16015319
10. Jain RK Molecular regulation of vessel maturation Nat Med 2003, 9(6):685-693 10.1038/nm0603-685 12778167
11. Kerbel RS Tumor angiogenesis: Past, present and the near future Carcinogenesis 2000, 21(3):505-515 10.1093/carcin/21.3.505 10688871
12. Kerbel RS Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed Cancer Cell 2005, 8(4):269-271 10.1016/j.ccr.2005.09.016 16226701
13. Casanovas O Hicklin DJ Bergers G Hanahan D Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 2005, 8(4):299-309 10.1016/j.ccr.2005.09.005 16226705
14. Pietras K Hanahan D A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer J Clin Oncol 2005, 23(5):939-952 10.1200/JCO.2005.07.093 15557593
15. Jaffe EA Nachman RL Becker CG Minick CR Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria J Clin Invest 1973, 52(11):2745-2756 302542 4355998 10.1172/JCI107470
16. Bishop ET Bell GT Bloor S Broom IJ Hendry NF Wheatley DN An in vitro model of angiogenesis: Basic features Angiogenesis 1999, 3(4):335-344 10.1023/A:1026546219962 14517413
17. Neubert K Haberland A Kruse I Wirth M Schimke I The ratio of formation of prostacyclin/thromboxane A2 in HUVEC decreased in each subsequent passage Prostaglandins 1997, 54(1):447-462 10.1016/S0090-6980(97)00063-4 9271783
18. Freedman DA Folkman J Maintenance of G1 checkpoint controls in telomerase-immortalized endothelial cells Cell Cycle 2004, 3(6):811-816 15118409
19. Freedman DA Folkman J CDK2 translational down-regulation during endothelial senescence Exp Cell Res 2005, 307(1):118-130 10.1016/ j.yexcr.2005.03.025 15922732
20. Erusalimsky JD Kurz DJ Endothelial cell senescence Handb Exp Pharmacol 2006:213-248 17001772
21. Sherman BT Huang da W Tan Q Guo Y Bour S Liu D Stephens R Baseler MW Lane HC Lempicki RA DAVID Knowledgebase: A gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis BMC Bioinformatics 2007, 8:426 2186358 17980028 10.1186/1471-2105-8-426
22. Jeong H Tombor B Albert R Oltvai ZN Barabasi AL The large-scale organization of metabolic networks Nature 2000, 407(6804):651-654 10.1038/35036627 11034217
23. Folkman J Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin Sci STKE 2006, 2006(354):pE35 10.1126/stke.3542006pe35 17003465
24. Giuriato S Ryeom S Fan AC Bachireddy P Lynch RC Rioth MJ van Riggelen J Kopelman AM Passegue E Tang F Folkman J Felsher DW Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch Proc Natl Acad Sci U S A 2006, 103(44):16266-16271 1637571 17056717 10.1073/pnas.0608017103
25. Baka S Clamp AR Jayson GC A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis Expert Opin Ther Targets 2006, 10(6):867-876 10.1517/14728222.10.6.867 17105373
26. Cabebe E Wakelee H Sunitinib: A newly approved small-molecule inhibitor of angiogenesis Drugs Today (Barc) 2006, 42(6):387-398 10.1358/ dot.2006.42.6.985633 16845442
27. Zakarija A Soff G Update on angiogenesis inhibitors Curr Opin Oncol 2005, 17(6):578-583 10.1097/01.cco.0000183672.15133.ab 16224236
28. Abdollahi A Schwager C Kleeff J Esposito I Domhan S Peschke P Hauser K Hahnfeldt P Hlatky L Debus J Peters JM Friess H Folkman J Huber PE Transcriptional network governing the angiogenic switch in human pancreatic cancer Proc Natl Acad Sci U S A 2007, 104(31):12890-12895 1931565 17652168 10.1073/pnas.0705505104
29. Sartore-Bianchi A Ricotta R Cerea G Maugeri MR Siena S Rationale and clinical results of multi-target treatments in oncology Int J Biol Markers 2007, 22(1 Suppl 4):S77-S87 17520585
30. Meyerhardt JA Mayer RJ Systemic therapy for colorectal cancer N Engl J Med 2005, 352(5):476-487 10.1056/NEJMra040958 15689586
31. Zimmermann GR Lehar J Keith CT Multi-target therapeutics: When the whole is greater than the sum of the parts Drug Discov Today 2007, 12(1-2):34-42 10.1016/j.drudis.2006.11.008 17198971
32. Marx J Cancer. Encouraging results for second-generation antiangiogenesis drugs Science 2005, 308(5726):1248-1249 10.1126/ science.308.5726.1248 15919970
33. D'Haeseleer P Liang S Somogyi R Genetic network inference: From co-expression clustering to reverse engineering Bioinformatics 2000, 16(8):707-726 10.1093/bioinformatics/16.8.707 11099257
34. Hartemink AJ Gifford DK Jaakkola TS Young RA Combining location and expression data for principled discovery of genetic regulatory network models Pac Symp Biocomput 2002:437-449 11928497
35. Pe'er D Regev A Elidan G Friedman N Inferring subnetworks from perturbed expression profiles Bioinformatics 2001, 17(Suppl 1):S215-24 11473012
36. Segal E Shapira M Regev A Pe'er D Botstein D Koller D Friedman N Module networks: Identifying regulatory modules and their condition-specific regulators from gene expression data Nat Genet 2003, 34(2):166-176 12740579
37. Iossifov I Krauthammer M Friedman C Hatzivassiloglou V Bader JS White KP Rzhetsky A Probabilistic inference of molecular networks from noisy data sources Bioinformatics 2004, 20(8):1205-1213 10.1093/bioinformatics/ bth061 14871876
38. Benson M Breitling R Network theory to understand microarray studies of complex diseases Curr Mol Med 2006, 6(6):695-701 10.2174/ 156652406778195044 17022739
39. Thomas R Paredes CJ Mehrotra S Hatzimanikatis V Papoutsakis ET A model-based optimization framework for the inference of regulatory interactions using time-course DNA microarray expression data BMC Bioinformatics 2007, 8(1):228 1940027 17603872 10.1186/1471-2105-8-228
40. Shou J Soriano R Hayward SW Cunha GR Williams PM Gao WQ Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression Proc Natl Acad Sci U S A 2002, 99(5):2830-2835 122433 11880635 10.1073/ pnas.052705299
41. Shou J Bull CM Li L Qian HR Wei T Luo S Perkins D Solenberg PJ Tan SL Chen XY Roehm NW Wolos JA Onyia JE Identification of blood biomarkers of rheumatoid arthritis by transcript profiling of peripheral blood mononuclear cells from the rat collagen-induced arthritis model Arthritis Res Ther 2006, 8(1):R28 1526586 16507131 10.1186/ar1883
42. Benjamini Y Hochberg Controlling the false discovery rate: A practical and powerful approach to multiple testing The Journal of Royal Statistical Society 1995, 57(1):289-300
43. Venables W Ripley B Modern Applied Statistics with S-PLUS New York, Springer-Verlag 1997